Nilotinib Counteracts P-Glycoprotein-Mediated Multidrug Resistance and Synergizes the Antitumoral Effect of Doxorubicin in Soft Tissue Sarcomas

Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib

(2010) Paul W. Manley et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib

(2010) Joan Maurel et al.   CANCER

Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway

(2010) Chang-Liang Peng et al.   CANCER BIOLOGY & THERAPY

Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomas

(2010) Blanca Homet Moreno et al.   Clinical & Translational Oncology

Targeting of p38 mitogen-activated protein kinases to early growth response gene 1 (EGR-1) in the human paclitaxel-resistance ovarian carcinoma cells

(2010) Meisong Lu et al.   Journal of Huazhong University of Science and Technology-Medical Sciences

Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice

(2010) Daniel J. DeAngelo et al.   LEUKEMIA & LYMPHOMA

Imatinib mesylate for children with dermatofibrosarcoma protuberans (DFSP)

(2010) Saskia L.M. Gooskens et al.   PEDIATRIC BLOOD & CANCER

Nilotinib (AMN107, Tasigna ® ) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters

(2009) Amit K. Tiwari et al.   BIOCHEMICAL PHARMACOLOGY

Extended kinase profile and properties of the protein kinase inhibitor nilotinib

(2009) Paul W. Manley et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors

(2009) A. W. Gramza et al.   CLINICAL CANCER RESEARCH

Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib

(2009) M. Montemurro et al.   EUROPEAN JOURNAL OF CANCER

Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters

(2009) A Davies et al.   LEUKEMIA

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

(2009) A Hochhaus et al.   LEUKEMIA

Nilotinib: A second-generation tyrosine kinase inhibitor for chronic myeloid leukemia

(2009) Massimo Breccia et al.   LEUKEMIA RESEARCH

Adaptor Protein Crk Induces Src-Dependent Activation of p38 MAPK in Regulation of Synovial Sarcoma Cell Proliferation

(2009) T. Watanabe et al.   MOLECULAR CANCER RESEARCH

Increased p38-MAPK is responsible for chemotherapy resistance in human gastric cancer cells

(2008) Xianling Guo et al.   BMC CANCER

Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases

(2008) Alfonso Quintás-Cardama et al.   Future Oncology

Inhibition of c-Myc Down-Regulation by Sustained Extracellular Signal-Regulated Kinase Activation Prevents the Antimetabolite Methotrexate- and Gemcitabine-Induced Differentiation in Non-Small-Cell Lung Cancer Cells

(2008) J. M. Serra et al.   MOLECULAR PHARMACOLOGY

Novel approaches to imatinib-and sunitinib-resistant GIST

(2008) Peter Reichardt   Current Oncology Reports